Walt Disney Co vs Cassava Sciences Inc — how do they compare? Walt Disney Co trades at $107.05 (market cap $180.87B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: Walt Disney Co is far larger — about 4590.6× Cassava Sciences Inc's market cap, and Walt Disney Co pays a 1.43% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Cassava Sciences Inc for 37 Days on average.
| DIS | FLNA | |
|---|---|---|
Market Cap | $180.87B | $39.40M |
Volume | 7,385,182 | 759,018 |
Sector | Media | Health |
52-Week High | $116.65 | $4.64 |
52-Week Low | $92.40 | $0.68 |
Typical Hold Time | 199 Days | 37 Days |
Enterprise Value | $221.73B | -$43.28M |
Dividend Yield | 1.43% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.93% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $91.4B to $94.4B in 2025 and net income surging to $12.4B. Recent earnings beats and a $60B parks investment highlight strategic expansion. Analyst consensus remains strongly positive with a $125.67 price target, representing 17% upside potential from current levels.
Disney presents a compelling investment opportunity with accelerating profitability and strategic investments in experiences and streaming. Key risks include free cash flow pressure from elevated capital expenditures and competitive streaming landscape challenges. The stock's current valuation at 21.6x P/E appears reasonable given growth trajectory, though execution on content investments and margin expansion will be critical for sustained outperformance.
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →